|Bid||4.5200 x 1000|
|Ask||4.5500 x 1300|
|Day's range||4.3400 - 4.6800|
|52-week range||1.3500 - 6.8200|
|Beta (5Y monthly)||2.15|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccine against infectious diseases, today announced that company’s Chief Executive Officer, Frederic Ors will participate at the Vaccines Panel of the 20th Annual Biotech in Europe Forum held on September 21-24, 2020.
IMV Inc. ("IMV" or the "Corporation") (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the IMV’s executive management team will participate at four upcoming virtual investor conferences in September:
IMV INC (IMV) delivered earnings and revenue surprises of 25.00% and -42.86%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?